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IDENTIFYING PATIENTS WITH PSYCHOSES IN 
A MEDICAID MANAGED CARE ORGANIZATION 
WITH CARVED-OUT BEHAVIORAL 
HEALTH SERVICES
Bachleda MJ1, Moxey E1, Goldfarb N1, Schaffer M2
1Office of Health Policy and Clinical Outcomes, Thomas 
Jefferson University, Philadelphia, PA, USA; 2Health Partners, 
Philadelphia, PA, USA
Continuity of care between physical and behavioral health
providers is a problem in today’s fragmented health care
system. Issues of privacy often do not allow sharing of
data among providers. For physical health providers and
insurers, the ability to identify patients with behavioral
health problems is important for care coordination and
targeting of disease management resources. OBJECTIVE:
Compare methods for identification of members with
psychoses using medical and pharmacy claims data in a
Medicaid HMO with a state-mandated behavioral health
carve-out. METHODS: Medical and pharmacy claims
data were reviewed for members 18 years or older identi-
fied by ICD-9CM codes 295–299.x or prescribed 90 days
of antipsychotic medications during calendar year 1998.
RESULTS: Of the 86,004 members with one year’s con-
tinuous enrollment, 776 had one or more medical claims
with a psychosis diagnosis and 2800 had used antipsy-
chotics. The 3166 unique members were categorized into
three groups: 410 members identified by both medical
and pharmacy claims, 366 identified by medical claims
only, and 2390 identified by pharmacy claims only. Iden-
tifying psychotic members on either medical or pharmacy
claims alone neglected 75% and 12% of the population
respectively. CONCLUSIONS: These results suggest a
majority of psychotic patients have not been recognized
by the physical health provider to have psychoses, are not
receiving physical as well as behavioral health services, or
physical providers are not coding these diagnoses. This
suggests continuity of care between the physical and be-
havioral health care carve-out providers is lacking. Fur-
ther data analysis will be performed to assess resource
use and patterns of care among these groups.
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ARE THE BRITISH GOVERNMENT’S 
HEALTHCARE REFORMS TARGETING 
PATIENT’S NEEDS?: EVIDENCE FROM A 
COMPARISON OF TWO GP SURVEYS ON 
MUSCULOSKELETAL CARE
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Clinical governance and Health Improvement Plans
(HIPs) targeted to patients’ primary healthcare needs are
central to the British government’s NHS reforms. The re-
forms obliged Primary Care Groups (PCGs) to heed pub-
lic concern over poor professional standards in the provi-
sion of NHS services. Real data on the impact of the
reforms is limited. The data presented here is novel. It
provides an annual assessment of the reforms’ effects on
primary care from the perspective of the patients’ doc-
tors, the General Practitioner (GP). OBJECTIVES: To
determine how PCGs are responding to the needs of GPs’
patients, and whether these needs are being attended to
better now than previously. METHODS: In November
1998, the Primary Care Rheumatology (PCR) society
mailed each of its members a questionnaire to assess the
impact of the Primary Care Act on musculoskeletal care.
A follow-up questionnaire was mailed in November
1999. Using Microsoft Excel, the numerical data was
quantified as means, medians or ranges, whilst free text
answers were summarised using categories based on the
responses. RESULTS: In November 1998 few HIPs were
concentrating on a prime area of concern to patients,
musculoskeletal care. In 1999, a gulf still exists between
health authorities’ perceptions of patients’ needs and
what GPs’ first-hand experience tells them. GPs’ financial
pressures are also growing and increasingly affecting
PCG drug budgets. CONCLUSIONS: GPs are struggling
to cope with the speed and scope of the reforms, with pa-
tients’ needs going unmet. With the current explosion in
new musculoskeletal medicines, the growing financial
pressures will be of concern to patients, politicians and
the pharmaceutical industry.
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ENTER THE DRAGON: PHARMACOECONOMICS 
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Pang F1, Tran G2
1University of York, York, UK; 2The Lewin Group, Bracknell, UK
OBJECTIVES: The South-East Asian region (China, South
Korea, Taiwan, the Philippines, Indonesia, Thailand,
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Hong Kong, Malaysia, Vietnam, Singapore and Japan)
has a large and ageing population with a high prevalence
of infectious and chronic disease and demand for phar-
maceuticals. Until recently Asia has been placed at the
top of every multinational pharmaceutical company’s list
of investment priorities and there has been growing inter-
est in the economic evaluation of pharmaceuticals. The
aim of this study is to examine recent developments and
the potential for pharmacoeconomics in Asia in the con-
text of financial economies, recent health reforms, regu-
lation, registration and reimbursement, the conduct of
clinical trials, and the availability of health economics ex-
pertise. METHODS: A systematic review involving data-
bases (MEDLINE, HEED, NHS EED) and hand-searches
of journals was conducted for economic evaluations orig-
inating in Asian countries to-date, and each identified
economic evaluation was then assessed for quality using
a modified checklist based on Drummond et al. (1997).
Simultaneously, multivariate techniques were used to ex-
plore relationships and trends between data on key eco-
nomic and health indicators, healthcare expenditures,
market sizes and epidemiological statistics of countries
within the Asian region. In addition membership lists
(e.g. iHEA, APHEN, ISTAHC, HESG) were scanned to
gauge approximate numbers of health economists operat-
ing within the region. Finally a review of the literature
supported by personal interviews was performed to de-
rive information on the nature of the health care environ-
ments and commercial operating conditions within the
region to set the results in context. RESULTS: Few eco-
nomic evaluations have been conducted in the Asian re-
gion to date (China  9, South Korea  2, Taiwan  6,
the Philippines  6, Indonesia  4, Thailand  32, Hong
Kong  16, Malaysia  4, Vietnam  3 and Singapore 
14 and Japan  31) covering a multitude of clinical ar-
eas. The majority of economic evaluations were cost-con-
sequence analyses and varied in quality. Very few eco-
nomic evaluations were commissioned by industry. As in
Europe, Asian countries differ widely in their methods of
healthcare financing, regulation and distribution and
their approaches to the pricing and reimbursement of
pharmaceuticals. Generally clinical trials conducted in
the Asian region tend to be small-scale studies as most
Asian countries accept the validity of well-controlled tri-
als elsewhere, which has implications for economic eval-
uation study design. No official guidance for the conduct
of economic evaluations exists for any of the countries in
Asia to date. Diseases common in the West such as Type
II diabetes, ischaemic heart disease, stroke, cancer, respi-
ratory illnesses, asthma, osteoporosis, and arthritis are
becoming increasingly prevalent in Asia and depression,
alcoholism and suicide are growing problems. CON-
CLUSIONS: Worldwide, economic evaluations are gen-
erating huge interest as new financial pressures are placed
on governments. Rapid healthcare reform is occurring
throughout the Asian region and it is likely that in the fu-
ture, pharmaceutical companies have to be far more ac-
countable for their products. Population numbers alone
dictate that Asia will evolve into the world’s biggest pur-
chasers of medicines, but at some point decision-makers
in the Asian region will require assessments of the costs
and benefits of pharmaceuticals. Up to now economic
evaluation is not well developed in Asia and much work
needs to be done. This research offers some insights for
pharmaceutical companies looking to develop strategies
for the economic evaluation of pharmaceuticals in Asia.
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ANALYSIS OF THE TOTAL COST AND 
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AND CONCURRENT CHRONIC ILLNESS
Garis RI1, Farmer KC2, Jacobs EW2
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Treatment of chronic illness represents significant cost,
accounting for approximately 75% of US health care ex-
penditures. These costs will likely increase as the US pop-
ulation ages. OBJECTIVE: To determine the total and
component costs in patients with one, and two concur-
rent chronic illnesses. METHODS: Data from 284,060
Oklahoma Medicaid patients from fiscal year 1995 com-
prised the study universe. Patients were classified into 23
chronic disease states by diagnosis and prescription drug-
disease evidence. The nine most prevalent chronic ill-
nesses were: psychosis, depression, cardiovascular illness,
congestive heart failure, diabetes, stomach illness, respi-
ratory illness/asthma, hypertension and anxiety. RE-
SULTS: As single illnesses, there were three levels of
yearly spending by ANOVA. Psychosis and depression
were the highest with costs of $6964 and $5505, respec-
tively. The next highest cost group ranged from $2320 to
$1634 and was composed of cardiovascular illness, con-
gestive heart failure, diabetes, stomach illness, and respi-
ratory illness. The low cost illnesses were hypertension
and anxiety with costs of $1351 and $1334, respectively.
MANOVA was employed to determine significant com-
ponent costs. Psychosis and depression utilized primarily
psychologist and hospital, respectively. Moderate cost
diseases utilized hospital most, then pharmacy. Low cost
illnesses used pharmacy and hospital equally. Two-
disease combinations displayed three levels of spending.
High, moderate and low cost single illnesses formed high,
moderate and low cost pairs, respectively. The psychosis
and depression pair was the highest cost of all pairs, with
total costs of $18,316. This represented a statistical inter-
action on cost. CONCLUSION: Supra-additive effects on
total and component costs were found in selected two-
disease combinations.
